Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Bristol Myers Squibb : Investigators at Bristol-Myers Squibb Co. Release New Data on Clinical Trials and Studies (A Systematic Review and Pooled Analysis of Select Safety...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/25/2017 | 09:18pm CEST

Investigators at Bristol-Myers Squibb Co. Release New Data on Clinical Trials and Studies (A Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical Trials)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Fresh data on Clinical Research - Clinical Trials and Studies are presented in a new report. According to news reporting out of Princeton, New Jersey, by NewsRx editors, research stated, "A systematic review of the Bristol-Myers Squibb normal healthy volunteers (NHVs) database identified phase 1 trials that included NHVs administered placebo with the aim of characterizing normal inter-and intraindividual safety parameter variability. Twenty-five single and multiple ascending dose studies, median duration 28 (2 to 63) days, were included in the pooled analysis (355 NHVs)."

Financial support for this research came from Bristol-Myers Squibb (see also Clinical Research - Clinical Trials and Studies).

Our news journalists obtained a quote from the research from Bristol-Myers Squibb Co., "Laboratory evaluations, vital signs, electrocardiograms, and adverse events were assessed. The most commonly occurring adverse event was headache (28 [7.9%] NHVs; 519.5 events/100 person-years). During the dosing period (on placebo), evaluations showed 5.1 events/100 measures of alanine aminotransferase and 7.3 events/100 measures of creatine kinase 1? above the upper limit of normal. Alanine aminotransferase and creatine kinase elevations occurred in 28 (7.9%) and 39 (11.0%) NHVs, respectively; 105 (30.3%) NHVs had low and 46 (13.3%) had high diastolic blood pressure."

According to the news editors, the research concluded: "This analysis may inform future study designs and provide a context for interpretation of safety signals in early phase clinical trials."

For more information on this research see: A Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical Trials. Journal of Clinical Pharmacology, 2017;():. Journal of Clinical Pharmacology can be contacted at: SAGE Publications, USA , 2455 Teller Road, Thousand Oaks, CA 91320, USA. (Sage Publications - www.sagepub.com/; Journal of Clinical Pharmacology - jcp.sagepub.com)

Our news journalists report that additional information may be obtained by contacting T.C. Young, Bristol-Myers Squibb, Princeton, NJ, United States. Additional authors for this research include S. Srinivasan, M.L. Vetter, V. Sethuraman, Z. Bhagwagar, R. Zwirtes, P. Narasimhan, T. Chuang and B.J Smyth.

Publisher contact information for the Journal of Clinical Pharmacology is: SAGE Publications, USA , 2455 Teller Road, Thousand Oaks, CA 91320, USA.

Keywords for this news article include: Kinase, Princeton, New Jersey, United States, Aminotransferase, Clinical Research, Enzymes and Coenzymes, North and Central America, Clinical Trials and Studies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
09:18p BRISTOL MYERS SQUIBB : Investigators at Bristol-Myers Squibb Co. Release New Dat..
05/24 BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Re..
05/23 BRISTOL MYERS SQUIBB : Merck's Momentum
05/22 BRISTOL-MYERS SQUIBB CO : Blog Coverage: Bristol-Myers Squibs Received EMA Valid..
05/19 BRISTOL MYERS SQUIBB : European Medicines Agency Validates Application for Brist..
05/18 BRISTOL MYERS SQUIBB : Studies from P.J. Mease et al in the Area of Psoriatic Ar..
05/18 BRISTOL MYERS SQUIBB : Trademark Application for "COBLIXRA" Filed
05/18 BRISTOL MYERS SQUIBB : and Calithera Biosciences Expand Collaboration Evaluating..
05/18 BRISTOL MYERS SQUIBB : Investigators at Bristol-Myers Squibb Describe Findings i..
05/18 BRISTOL MYERS SQUIBB : An Application for the Trademark "CLATAZEV" Has Been File..
More news
Sector news : Pharmaceuticals - NEC
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03:34p Is OncoMed A Contrarian Buy?
02:52p FDA drug approvals rebound from last year, up over 100% yoy
01:07p FDA chief says agency needs to play a role in constraining drug prices by eas..
08:48a Keytruda's Next Advance Encroaches On Opdivo And Tecentriq Territory
05/24 Exelixis Could Still Be A Buy
Advertisement
Financials ($)
Sales 2017 20 267 M
EBIT 2017 5 463 M
Net income 2017 4 622 M
Finance 2017 202 M
Yield 2017 2,94%
P/E ratio 2017 19,18
P/E ratio 2018 17,55
EV / Sales 2017 4,36x
EV / Sales 2018 4,21x
Capitalization 88 665 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 57,2 $
Spread / Average Target 6,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Laurie H. Glimcher Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-7.24%89 126
JOHNSON & JOHNSON10.68%342 817
ROCHE HOLDING LTD.15.18%237 610
NOVARTIS AG6.68%213 719
PFIZER INC.-1.32%191 279
MERCK & CO., INC.10.29%175 160
More Results